Search

Your search keyword '"Segolodi, Tebogo M."' showing total 6 results
Start Over Author "Segolodi, Tebogo M." Search Limiters Available in Library Collection
6 results on '"Segolodi, Tebogo M."'

2. Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis

Author

Haaland, Richard E., primary, Holder, Angela, additional, Pau, Chou-Pong, additional, Swaims-Kohlmeier, Alison, additional, Dawson, Carolyn, additional, Smith, Dawn K., additional, Segolodi, Tebogo M., additional, Thigpen, Michael C., additional, Paxton, Lynn A., additional, Parsons, Teresa L., additional, Hendrix, Craig W., additional, and Hart, Clyde E., additional

Published
2017
Full Text
View/download PDF

5. CD4cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis

Author

Chirwa, Lovemore I., Johnson, Jeffrey A., Niska, Richard W., Segolodi, Tebogo M., Henderson, Faith L., Rose, Charles E., Li, Jin-fen, Thigpen, Michael C., Matlhaba, Onkabetse, Paxton, Lynn A., and Brooks, John T.

Abstract

We examined CD4cell count and plasma viral load patterns among Botswana TDFFTC Oral HIV Prophylaxis Trial (TDF2 study) participants who seroconverted, comparing participants assigned to receive tenofoviremtricitabine with participants assigned to receive placebo. We also evaluated for antiretroviral drug resistance among the breakthrough HIV infections. Among nine seroconverters assigned to tenofoviremtricitabine and 24 to placebo, there were no significant differences in their CD4cell count or viral load profiles over time. Of the four participants who seroconverted on-study while receiving tenofoviremtricitabine, none became infected as a result of drug-resistant HIV; moreover, no resistance mutations emerged following seroconversion.

Published
2014
Full Text
View/download PDF

6. Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis.

Author

Haaland RE, Holder A, Pau CP, Swaims-Kohlmeier A, Dawson C, Smith DK, Segolodi TM, Thigpen MC, Paxton LA, Parsons TL, Hendrix CW, and Hart CE

Subjects
Adult, Female, HIV Reverse Transcriptase antagonists & inhibitors, Humans, Lymphocyte Activation drug effects, Male, Phosphorylation, Substrate Specificity, Viral Load, CD4-Positive T-Lymphocytes drug effects, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination pharmacokinetics, HIV Infections prevention & control, Pre-Exposure Prophylaxis, Reverse Transcriptase Inhibitors pharmacokinetics
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results